Recruiting Macular Degeneration Studies in Bakersfield
Extension Study for the Port Delivery System With Ranibizumab (Portal)
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) w...
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by ...
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration...
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-...
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W)....
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)
RGX-314 is being developed as a potential novel one-time gene therapy treatment for the treatment of neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by loss of v...
Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)
This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV....
About Macular Degeneration Clinical Trials in Bakersfield
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in Americans over 50, affecting over 11 million people. Wet (neovascular) AMD involves abnormal blood vessel growth under the retina, while dry AMD involves gradual thinning of the macula and accumulation of drusen deposits. Current treatment for wet AMD relies on anti-VEGF injections (ranibizumab, aflibercept, faricimab), with newer high-dose and extended-interval formulations reducing treatment burden. For geographic atrophy (advanced dry AMD), complement inhibitors like pegcetacoplan (Syfovre) represent the first approved treatments. Clinical trials are testing gene therapies, implantable drug delivery systems, stem cell therapies, and novel targets beyond VEGF for both wet and dry AMD.
There are currently 7 macular degeneration clinical trials recruiting participants in Bakersfield, CA. These studies are seeking a combined 2,665 participants. Research is being sponsored by Hoffmann-La Roche, AbbVie, 4D Molecular Therapeutics and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Macular Degeneration Clinical Trials in Bakersfield — FAQ
Are there macular degeneration clinical trials in Bakersfield?
Yes, there are 7 macular degeneration clinical trials currently recruiting in Bakersfield, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Bakersfield?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Bakersfield research site will contact you about next steps.
Are clinical trials in Bakersfield free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Bakersfield studies also compensate for your time and travel.
What macular degeneration treatments are being tested?
The 7 active trials in Bakersfield are testing new therapies including novel drugs, biologics, and treatment approaches for macular degeneration.
Data updated March 2, 2026 from ClinicalTrials.gov